IP Library Granted Patent US 7,772,848
Granted Patent B2
US 7,772,848 · App. 12/255,282 · Granted Aug 10, 2010

Method of operation for a magnetic resonance imaging suite

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,772,848
App. No.
12/255,282
Granted
Aug 10, 2010
Kind
B2
Abstract

A method of operation for a magnetic resonance imaging suite. A power supply of magnetic resonance injector system receives electrical power from an AC power outlet, both of which are located outside of a shielded room of the magnetic resonance imaging suite. Electrical power from the power supply of the magnetic resonance injector system is conveyed (via an appropriate power connection) into the shielded room of the magnetic resonance imaging suite and to a component (e.g., a power head) of the magnetic resonance injector system located inside the shielded room. While this electrical power is being conveyed, radio frequency energy emitted from the power connection is being filtered.

Claims (22)

1. A medical imaging suite comprising:

a shielded room having walls that include electromagnetic shielding;

an AC power outlet;

an MRI unit comprising a magnet that is located inside the shielded room; and a power injector system comprising:

a power head located inside the shielded room, the power head being configured to operate a syringe in order to dispense contrast media from the syringe;

a power supply accessing and receiving AC power from the AC power outlet and converting the AC power to DC power; and

a power connection configured to convey power from the power supply to the power head, wherein the power connection comprises

a battery compartment toward which power from the power supply is conveyed and from which power is conveyed to the power head.

2. The imaging suite of claim 1 , wherein the power connection comprises a radio frequency filter.

3. The imaging suite of claim 2 , wherein the radio frequency filter grounds conductive shields of the power connection.

4. The imaging suite of claim 2 , wherein the radio frequency filter attenuates RF noise within a rejection frequency band selected to correspond to the RF frequencies used by the MRI unit.

5. The imaging suite of claim 1 , wherein the battery compartment is devoid of a battery.

6. The imaging suite of claim 1 , further comprising:

a control panel located outside the shielded room for generating data signals in order to control the power head; and

a data connection configured to convey data signals from the control panel to the power head.

7. The imaging suite of claim 1 , wherein the AC outlet is located outside the shielded room.

8. The imaging suite of claim 1 , wherein the power supply is located outside the shielded room.

9. The imaging suite of claim 1 , wherein the power connection comprises a cable configured to convey power from the power supply toward the battery compartment of the injector system.

10. The imaging suite of claim 1 , wherein the power connection comprises a cable configured to convey power from the battery compartment of the injector system into the power head of the injector system.

11. The imaging suite of claim 1 , wherein the power head comprises an ultrasonic motor.

12. The imaging suite of claim 1 further comprising a syringe mounted to the power head of the power injector system.

13. The imaging suite of claim 12 further comprising contrast media disposed within the syringe.

Assignments (2)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: LIEBEL-FLARSHEIM COMPANY LLC
Reel/Frame 037172/0094 →